Genetic Variations of HSD11B2 in Hypertensive Patients and in the General Population, Six Rare Missense/Frameshift Mutations

Abstract

Mutations in the gene encoding 11β-hydroxysteroid dehydrogenase type 2, HSD11B2, cause a rare monogenic juvenile hypertensive syndrome called apparent mineralocorticoid excess (AME). In AME, defective HSD11B2 enzyme activity results in overstimulation of the mineralocorticoid receptor (MR) by cortisol, causing sodium retention, hypokalemia, and salt-dependent hypertension. Here, we have studied whether genetic variations in HDS11B2 are implicated in essential hypertension in Japanese hypertensives and the general population. By sequencing the entire coding region and the promoter region of HDS11B2 in 953 Japanese hypertensives, we identified five missense mutations in 11 patients (L14F, n=5; R74H, n=1; R147H, n=3; T156I, n=1; R335H, n=1) and one novel frameshift mutation (4884Gdel, n=1) in a heterozygous state, in addition to 19 genetic variations. All genetic variations identified were rare, with minor allele frequencies less than 0.005. Four of 12 patients with the missense/frameshift mutations showed renal failure. Four missense mutations, L14F, R74H, R147H, and R335H, were successfully genotyped in the general population, with a sample size of 3,655 individuals (2,175 normotensives and 1,480 hypertensives). Mutations L14F, R74H, R147H, and R335H were identified in hypertensives (n=6, 8, 3, and 0, respectively) and normotensives (n=8, 12, 5, and 0, respectively) with a similar frequency, suggesting that these missense mutations may not strongly affect the etiology of essential hypertension. Since the allele frequency of all of the genetic variations identified in this study was rare, an association study was not conducted. Taken together, our results indicate that missense mutations in HSD11B2 do not substantially contribute to essential hypertension in Japanese.

References

  1. 1

    Agarwal AK, Monder C, Eckstein B, et al: Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase. J Biol Chem 1989; 264: 18939–18943.

  2. 2

    Albiston AL, Obeyesekere VR, Smith RE, et al: Cloning and tissue distribution of the human 11beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105: R11–R17.

  3. 3

    Tannin GM, Agarwal AK, Monder C, et al: The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 1991; 266: 16653–16658.

  4. 4

    Agarwal AK, Mune T, Monder C, et al: Cloning of cDNA encoding an NAD+-dependent isoform of 11beta-hydroxysteroid dehydrogenase in sheep kidney. Endocr Res 1995; 21: 389–397.

  5. 5

    Walker BR, Campbell JC, Williams BC, et al: Tissue-specific distribution of the NAD+-dependent isoform of 11beta-hydroxysteroid dehydrogenase. Endocrinology 1992; 131: 970–972.

  6. 6

    New MI, Levine LS, Biglieri EG, et al: Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977; 44: 924–933.

  7. 7

    Geller DS : A mineralocorticoid receptor mutation causing human hypertension. Curr Opin Nephrol Hypertens 2001; 10: 661–665.

  8. 8

    Ferrari P : Genetics of the mineralocorticoid system in primary hypertension. Curr Hypertens Rep 2002; 4: 18–24.

  9. 9

    Dave-Sharma S, Wilson RC, Harbison MD, et al: Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1998; 83: 2244–2254.

  10. 10

    Ferrari P, Krozowski Z : Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int 2000; 57: 1374–1381.

  11. 11

    Ferrari P, Lovati E, Frey FJ : The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. J Hypertens 2000; 18: 241–248.

  12. 12

    Mune T, Rogerson FM, Nikkila H, et al: Human hypertension caused by mutations in the kidney isozyme of 11beta-hydroxysteroid dehydrogenase. Nat Genet 1995; 10: 394–399.

  13. 13

    Li A, Tedde R, Krozowski ZS, et al: Molecular basis for hypertension in the “type II variant” of apparent mineralocorticoid excess. Am J Hum Genet 1998; 63: 370–379.

  14. 14

    Nunez BS, Rogerson FM, Mune T, et al: Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. Hypertension 1999; 34: 638–642.

  15. 15

    Odermatt A, Dick B, Arnold P, et al: A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. J Clin Endocrinol Metab 2001; 86: 1247–1252.

  16. 16

    Lavery GG, Ronconi V, Draper N, et al: Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 2003; 42: 123–129.

  17. 17

    Quinkler M, Bappal B, Draper N, et al: Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Mol Cell Endocrinol 2004; 217: 143–149.

  18. 18

    Kitanaka S, Katsumata N, Tanae A, et al: A new compound heterozygous mutation in the 11beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 1997; 82: 4054–4058.

  19. 19

    Wilson RC, Nimkarn S, New MI : Apparent mineralocorticoid excess. Trends Endocrinol Metab 2001; 12: 104–111.

  20. 20

    Ugrasbul F, Wiens T, Rubinstein P, et al: Prevalence of mild apparent mineralocorticoid excess in Mennonites. J Clin Endocrinol Metab 1999; 84: 4735–4738.

  21. 21

    Brand E, Chatelain N, Mulatero P, et al: Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998; 32: 198–204.

  22. 22

    Smolenicka Z, Bach E, Schaer A, et al: A new polymorphic restriction site in the human 11beta-hydroxysteroid dehydrogenase type 2 gene. J Clin Endocrinol Metab 1998; 83: 1814–1817.

  23. 23

    Lovati E, Ferrari P, Dick B, et al: Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 1999; 84: 3745–3749.

  24. 24

    Kamide K, Takiuchi S, Tanaka C, et al: Three novel missense mutations of WNK4, a kinase mutated in inherited hypertension, in Japanese hypertensives: implication of clinical phenotypes. Am J Hypertens 2004; 17: 446–449.

  25. 25

    Kamide K, Tanaka C, Takiuchi S, et al: Six missense mutations of the epithelial sodium channel beta and gamma subunits in Japanese hypertensives. Hypertens Res 2004; 27: 333–338.

  26. 26

    Kamide K, Yang J, Kokubo Y, et al: A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: implication of clinical phenotypes. Hypertens Res 2005; 28: 703–709.

  27. 27

    Matayoshi T, Kamide K, Takiuchi S, et al: The thiazide-sensitive Na+-Cl cotransporter gene, C1784T, and adrenergic receptor-β3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertens Res 2004; 27: 821–833.

  28. 28

    Takiuchi S, Mannami T, Miyata T, et al: Identification of 21 single nucleotide polymorphisms in human hepatocyte growth factor gene and association with blood pressure and carotid atherosclerosis in the Japanese population. Atherosclerosis 2004; 173: 301–307.

  29. 29

    Kokubo Y, Inamoto N, Tomoike H, et al: Association of genetic polymorphisms of sodium-calcium exchanger 1 gene, NCX1, with hypertension in a Japanese general population. Hypertens Res 2004; 27: 697–702.

  30. 30

    Tanaka C, Mannami T, Kamide K, et al: Single nucleotide polymorphisms in the interleukin-6 gene associated with blood pressure and atherosclerosis in a Japanese general population. Hypertens Res 2005; 28: 35–41.

  31. 31

    Tanaka C, Kamide K, Takiuchi S, et al: An alternative fast and convenient genotyping method for the screening of angiotensin converting enzyme gene polymorphisms. Hypertens Res 2003; 26: 301–306.

  32. 32

    Wilson RC, Dave-Sharma S, Wei JQ, et al: A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci U S A 1998; 95: 10200–10205.

  33. 33

    Cohen JC, Kiss RS, Pertsemlidis A, et al: Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305: 869–872.

  34. 34

    Yang J, Kamide K, Kokubo Y, et al: Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population. J Hypertens 2005; 23: 1497–1505.

  35. 35

    Agarwal AK, Mune T, Monder C, et al: NAD+-dependent isoform of 11beta-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. J Biol Chem 1994; 269: 25959–25962.

  36. 36

    Zaehner T, Plueshke V, Frey BM, et al: Structural analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease. Kidney Int 2000; 58: 1413–1419.

  37. 37

    Antonarakis SE, Nomenclature Working Group: Recommendations for a nomenclature system for human gene mutations. Hum Mut 1998; 11: 1–3.

Download references

Author information

Correspondence to Kei Kamide.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kamide, K., Kokubo, Y., Hanada, H. et al. Genetic Variations of HSD11B2 in Hypertensive Patients and in the General Population, Six Rare Missense/Frameshift Mutations. Hypertens Res 29, 243–252 (2006). https://doi.org/10.1291/hypres.29.243

Download citation

Keywords

  • HSD11B2
  • missense mutation
  • genetic variation
  • essential hypertension
  • salt-sensitivity

Further reading

  • HSD11B2 CA-repeat and sodium balance

    • Tomoatsu Mune
    • , Hiroyuki Morita
    • , Nobuki Takada
    • , Yoritsuna Yamamoto
    • , Yukinori Isomura
    • , Tetsuya Suwa
    • , Jun Takeda
    • , Perrin C White
    •  & Kohei Kaku

    Hypertension Research (2013)